drugset
drugset / Trial / NCT04072315

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

NCT04072315 ↗

Phase 2 Completed 9 enrolled Pliant Therapeutics, Inc. Stanford University · collab
Non-randomizedCrossoverOpen-labelTreatment

Summary

A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.

Timeline

Start
2020-02-13
Primary completion
2022-06-27
Completion
2022-07-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject bexotegrast Small molecule 60 mg Oral
Subject bexotegrast Small molecule 80 mg Oral
Subject bexotegrast Small molecule 120 mg Oral
Subject bexotegrast Small molecule 240 mg Oral
Subject bexotegrast Small molecule 320 mg Oral

Indications

idiopathic pulmonary fibrosis